首页 > 文献资料
-
VEGF在维吾尔族非小细胞肺癌中的表达及临床意义
肺癌的发病率和死亡率已居我国城市肿瘤的首位,并且75%一80%的肺癌是非小细胞肺癌(non-small cell lung cancer NSCLC),癌细胞的侵袭转移是影响肺癌预后的重要因素,新生血管是绝大多数实体瘤复发和转移的重要机制之一,血管内皮因子(vascular endothelialgrowth factor,VEGF)通过与受体结合,刺激内皮细胞的增殖、移行,增加血管的通透性,促进血管的生成[1].但国内研究对象多是汉族,而在新疆的维吾尔族,非小细胞肺癌患者中VEGF的表达状态是怎样的还研究甚少,因次我们研究了VEGF在维吾尔族非小细胞肺癌中的表达,现报告如下:
-
养阴清肺方治疗进展期非小细胞肺癌的临床研究
非小细胞肺癌(non-small cell lung cancer, NSCLC)对化疗的敏感性较差,我们自1995~2000年应用养阴清肺方治疗本病,取得了满意的效果,现报告如下.
-
艾迪注射液联合TP方案治疗非小细胞肺癌60例观察
我们采用艾迪注射液联合TP方案治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)效果较好,报告如下.1 临床资料共60例,均为本院2006年6月~2008年4月中晚期NSCLC患者,随机分两组各30例.治疗组男21例,女9例;年龄35~72岁,中位年龄55岁;腺癌16例,鳞癌12例,鳞腺癌1例,未分型1例;初治12例,复治18例;Ⅲ期14例,Ⅳ期16例;KPS评分60~80分,中位KPS评分70分.对照组男20例,女10例;年龄37~73岁,中位年龄57岁;腺癌16例,鳞癌11例,鳞腺癌2例,未分型1例;初治13例,复治17例;Ⅲ期15例,Ⅳ期15例;KPS评分60~90分,中位KPS评分70分.
-
艾迪注射液联合TP方案治疗非小细胞肺癌60例观察
我们采用艾迪注射液联合TP方案治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)效果较好,报告如下.1 临床资料共60例,均为本院2006年6月~2008年4月中晚期NSCLC患者,随机分两组各30例.治疗组男21例,女9例;年龄35~72岁,中位年龄55岁;腺癌16例,鳞癌12例,鳞腺癌1例,未分型1例;初治12例,复治18例;Ⅲ期14例,Ⅳ期16例;KPS评分60~80分,中位KPS评分70分.对照组男20例,女10例;年龄37~73岁,中位年龄57岁;腺癌16例,鳞癌11例,鳞腺癌2例,未分型1例;初治13例,复治17例;Ⅲ期15例,Ⅳ期15例;KPS评分60~90分,中位KPS评分70分.
-
非小细胞肺癌抗血管生成治疗进展
标准化疗是占肺癌80%[1]以上的非小细胞肺癌(non-small cell lung cancer,NSCLC)常用的治疗手段,但有效率(response rate,RR)仅为25%~35%.疾病进展时间(time to progression,TTP)为4个月到6个月,中位生存期(median survival time,MST)为8到10个月,1年生存率30%~40%,2年生存率为10%~15%,5年生存率小于5%[2-4].自上世纪70年代Folkman等提出了"肿瘤生长、转移依赖于血管生成"的学说后,抗血管生成已成为肿瘤生物靶向治疗研究的主要方向,也成为非小细胞肺癌治疗的又一热点.
-
肺癌患者血清肿瘤标志物联合检测的临床价值研究
目的:探讨5种肺癌血清肿瘤标志物联合检测的临床价值;方法:应用电化学发光法检测62例肺癌患者、21例健康人和33例肺部良性疾病患者血清中癌抗原125(CA125)、癌抗原19-9(CA19-9)、癌胚抗原(CEA)、细胞角蛋白l9(CYFRA21-1)和神经特异性烯醇化酶(NSE)的含量,计算检测的阳性率及联合检测的敏感性和特异性;结果:肺癌患者的5种血清肿瘤标志物阳性率均高于健康体检组和肺部良性疾病组,差异有统计学意义(P<0.05);在25种联合检测方案中,三联方案CA199+CEA+NSE的特异性与敏感性均较高,与其他组相比具有统计学意义(P<0.O5);结论:合理选择阳性率高的血清肿瘤标志物进行组合,对于提高肺癌筛选的敏感性及特异性具有一定的临床价值。
-
"多烯他赛+DDP"治疗晚期非小细胞肺癌36例疗效观察
非小细胞肺癌(nonsmall cell lung cancer, NSCLC)是一种常见肿瘤,我国发病率呈逐年增高趋势,大多数患者就诊时已经不可手术或有远处转移,寻求有效的治疗方法是目前迫切需要解决的问题,对此类患者一般采取以化疗为主的综合治疗.多烯他赛(docetaxel)是治疗NSCLC主要化疗药物,能够明显改善NSCLC患者的预后和生活质量.
-
继发性肺源性食管癌2例报告及文献复习
食管恶性肿瘤基本上都是源于食管黏膜上皮的原发性肿瘤,主要是鳞状上皮细胞癌,约占90%~95%[1],而非鳞状上皮细胞癌仅占4.1%~5.08%[2]。继发性鳞状上皮细胞性食管癌尚未见文献报道。我们收治2例源于局部晚期非小细胞肺癌( locally advanced non-small-cell lung cancer, LANSCLC),直接浸润或淋巴引流扩展引发的继发性食管鳞状上皮细胞癌,称之为继发性肺源性食管癌,临床非常罕见,命名准确与否,结合文献复习,提供商榷。
-
Objective:To explore the effect of ibandronate on the proliferation and the expression of human telomerase reverse transcriptase (hTERT) of non-small cell lung cancer (NSCLC) A549 cell line in vitro. Methods: Methyl thiazolyl tetrazolium (MTT) assay, microscope, flow cytometry (FCM) and semi-quantitative RT-PCR were employed to detect the cell proliferation, cell cycle as well as the morphological change and the expression of hTERT mRNA of A549 cell line. Results:The data showed that ibandronate could effectively inhibit the proliferation of A549 cell line in time-and concentration-dependent. Under the microscope, the lfoating cells increased gradually as the drug concentration increasing. FCM detection showed that ibandronate could induce the cell cycle stopped in G0/G1 phase and downregulation expression of hTERT. Conclusion:Ibandronate can inhibit the proliferation of A549 cell line in vitro, whose mechanism may be associated with cell cycle arrestted in phase G0/G1 and downregulation expression of hTERT.
-
Objective:To explore the expression of ezrin and its signiifcance in non-small cell lung cancer (NSCLC). Methods:The expression of ezrin in 81 NSCLC patients were examined by immunohistochemical staining Envision method, and its relationships with the clinopathologic features and other indexes were analyzed. Results:The high expression rate of ezrin in NSCLC was 59.26% (48/81) and significantly correlated with lymph node metastasis (P < 0.05), but not associated with gender, histologic subtype, differentiation, TNM stages or smoking. The K-M survival analysis demonstrated that patients with the over-expression of ezrin were obviously poorer than those with low-expression of ezrin (P<0.05). Conclusion:The expression of ezrin may be associated with metastasis of NSCLC, can be as an important marker for evaluating the prognosis of NSCLC patients.
-
Objective: To analyze the clinical features of lung cancer diagnosed by bronchoscopy. Methods:The clinical features of2168 patients with lung cancer diagnosed by bronchoscopy were retrospectively analyzed, including gender, age, pathological type, diseased region, manifestations under bronchoscopy and methods of drawing materials. Results:The ratio of male/female was 4.8:1 and the peak onset age was 60~69 years old. The major pathological type was squamous cell carcinoma (44.5%), then adenocarcinoma (25.9%) and small cell lung cancer (18.3%). The incidence of squamous cell carcinoma was the highest in males (50.6%), while that of adenocarcinoma in females (56.2%). The positive diagnostic rates of forceps biopsy, brush biopsy, bronchial alveolar lavage and transbronchial needle aspiration were 81.6%, 49.4%, 18.2% and 62.6%, respectively, whereas that of biopsy combined with brush biopsy came up to 89.0%. Conclusion: Bronchoscopy is an important method in diagnosis of lung cancer. Different ages and genders of patients with lung cancer have different onset, and the distribution of pathological types is diverse. Attaching more importance to bronchoscopy and improving biopsy technique can signiifcantly improve the diagnostic rate and provide reliable evidences for clinical treatment.